Prasco Laboratories (Prasco) has signed a distribution and supply agreement with Stiefel Laboratories (Stiefel), a GlaxoSmithKline company, for Clobetasol Propionate Foam 0.05%, the latest product in Prasco’s line of authorised generics.
As per the agreement, Prasco is expected to market and distribute Clobetasol Propionate Foam 0.05% in 50g and 100g canisters in the US. It is indicated for the short-term treatment of burning and itching caused by moderate to severe skin diseases of the scalp. It may also be used for psoriasis.
Thomas Arington, CEO of Prasco, said: “We are pleased to provide pharmacists and consumers with the authorised generic of Olux. As a Prasco authorised generic, Clobetasol Propionate Foam will provide patients with the same quality and experience as the brand product. We are especially pleased to expand our relationship with Stiefel and GSK.”
Bill Humphries, president of Stiefel, said: “Through our arrangement with Prasco, GlaxoSmithKline is able to expand patient access to our products by bringing brand quality to the generic marketplace. We are proud of our arrangement with Prasco.”